ArticleCanadian journal of gastroenterology & hepatology2025
The Value of TyG-Related Indices in Evaluating MASLD and Significant Liver Fibrosis in MASLD.
Article in Canadian journal of gastroenterology & hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Triglyceride glucose-body mass index as a practical screening tool for metabolic dysfunction-associated steatotic liver disease in older adults: A community-based cohort study.Asia Pacific journal of clinical nutrition · 2026Article
- Article
- Clinical Utility of the Triglyceride-Glucose Index in Assessing Hepatic Steatosis Severity Within the MASLD Spectrum.Diagnostics (Basel, Switzerland) · 2026Article
- Personalized MASLD and liver fibrosis risk assessment for adults: glycemic status determines optimal choice of non-invasive indices.Diabetology & metabolic syndrome · 2025Article
- CUN‑BAE predicts risk of metabolic dysfunction-associated steatotic liver disease: A prospective cohort study in non‑obese Chinese adults.Scientific reports · 2025Article
- Diagnostic Accuracy of Anthropometric and Metabolic Indicators for Predicting MASLD: Evidence from a Large Cohort of Spanish Workers Using FLI and LAP.Medical sciences (Basel, Switzerland) · 2025Article
- Triglyceride-glucose-waist circumference index: A powerful tool for metabolic dysfunction-associated steatotic liver disease.World journal of hepatology · 2025Review
- Hypersensitive C-reactive protein-atherogenic index as a novel marker for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes mellitus.Frontiers in endocrinology · 2025Article
- Analysis of the Association Between TG/HDL, TyG, TyG-BMI, and ZJU Indices with Metabolic Dysfunction-Associated Fatty Liver Disease in Patients with Type 2 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- The C-reactive Protein-Triglyceride-Glucose Index in Relation to Liver Disease.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.